Search Results
Your search for Blood matches 4668 pages
Showing 1701 - 1750HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC). The results of the phase II trial were shared ...
TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy
The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
Paul G. Marks, MD, Visionary Leader of Memorial Sloan Kettering Cancer Center, Dies at 93
In 1980, Paul G. Marks, MD, became the President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK), the oldest and largest private cancer center in the world. Over his 19-year reign, he is credited with setting MSK on a more scientific course by encouraging innovative...
The Story of Three Patients With Leukemia
The human drama within the oncology world is a never-ending story of triumph, tragedy, and all of the valiant efforts and human emotions in between. The doctor-patient relationship in oncology is deeper and longer than in most medical specialties due to the life-and-death stakes at play after a...
Ancestry and Molecular Makeup of Cancer Evaluated in New Study
A new study by researchers from the National Cancer Institute (NCI) Cancer Genome Analysis Network, a collaborative group with investigators in the United States, Canada and Europe, provides the most comprehensive look to date at the effect of ancestry on the molecular makeup of normal and...
Artificial Blood Substitute
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Radium Era: 1916–1945 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
NIH Aims to Quantify Undetected Cases of Coronavirus Infection
A new study has begun recruiting at the National Institutes of Health (NIH) in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes COVID-19, have antibodies to the virus. The presence of antibodies in...
Robert Bona, MD, Named Director of Benign Hematology Program at Yale Cancer Center Smilow Cancer Hospital
Yale Cancer Center has announced the appointment of Robert Bona, MD, as Professor of Medicine (Hematology) and inaugural Director of the Benign Hematology Program at Smilow Cancer Hospital. He will also join as Medical Director of the Hemophilia Treatment Center for the Pediatric Hematology &...
Despites Advances, Treatment-Related Sequelae Remain Problematic in Pediatric Neuro-oncology
The management of pediatric brain and spinal cord tumors is extremely complex, as are the survivorship issues in this highly vulnerable patient population. To shed light on the current clinical reality in this setting, The ASCO Post recently spoke with Katherine E. Warren, MD, an internationally...
Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, 2020, mitomycin gel was approved for the treatment of adult patients with low-grade upper tract urothelial cancer.1,2 Mitomycin gel is for pyelocalyceal use alone and not for intravenous, topical, or oral administration. Supporting Efficacy Data Approval was based on findings in the...
Luspatercept-aamt for Anemia in Adults With Myelodysplastic Syndromes
On April 3, 2020, luspatercept-aamt was approved in the treatment of anemia failing to respond to an erythropoiesis-stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks.1,2 The treatment is geared toward adult patients with very low– to intermediate-risk myelodysplastic ...
Lessons Learned on Rotation at COVID-19 Inpatient Service at New York City Hospital
AS I WRITE TO YOU, I am happy to report I have just completed a 7-day rotation at the COVID-19 inpatient service at my hospital in New York City! Overall, it was a positive experience, despite the occasional sad and scary moments. I left the service feeling uplifted and fulfilled. I am glad to have ...
Detecting Relapse in Patients With Lymphoma in First Remission: Value of Surveillance Laboratory Testing
In a single-institution retrospective study reported in JCO Oncology Practice, Lynch et al found that routine laboratory surveillance testing had limited value in detecting relapse in patients with classical Hodgkin lymphoma in first remission. Study Details The study involved 235 patients at...
Cancer Care at Tata Memorial Centre During the COVID-19 Pandemic
In correspondence published in The New England Journal of Medicine, two practitioners from Tata Memorial Centre, India’s largest cancer center, describe measures taken to continue providing cancer care during the COVID-19 pandemic in India. As related by the authors, scaling back of operations at...
FDA Approves Pomalidomide for Kaposi Sarcoma
On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...
New Study Shows Patients With Cancer Had Lower Rates of Detected COVID-19 Antibodies vs Health-Care Workers
Results from an analysis involving both patients with cancer and health-care workers at Centre Léon Bérard in Lyon, France, showed that patients with cancer had a significantly lower detection rate of SARS-CoV-2 antibodies 15 days or more after COVID-19 symptoms and a positive reverse transcription ...
Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women with no history of cancer. The test, called DETECT-A, identified 10 different cancer types, 65% of which were early-stage...
In ‘Remembering Mum,’ Siblings Honor Their Mother With Action and Innovation
It’s one of the worst things Claire Paxman can recall: She’s 14 years old, using orange-handled kitchen scissors to cut her mother’s hair. “You shouldn’t be standing in the bathroom cutting your mom’s hair because of chemotherapy,” said Claire as she describes that defining childhood moment when ...
Ongoing Efforts Toward Vaccine Development for COVID-19
Coronavirus disease 2019 (COVID-19) is spreading throughout the world, and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of an experimental vaccine candidate have already begun in the Seattle area. Although the...
Yoga for Pediatric and Adolescent Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Despite significant improvements reported in survival rates, symptom management in pediatric...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
The Role of Adipose Tissue in Cancer Aggressiveness
Over the past decade, obesity has been linked to an increased risk and aggressiveness of numerous cancer types. Many biologic activities within adipose tissue change with obesity and may contribute to carcinogenesis and the initiation of cancer. To shed light on the current state of knowledge in...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, Myeloma, and Myelodysplastic Syndromes
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
Expert Point of View: Virginia Kaklamani, MD, DSc, and Minetta Liu, MD
Virginia Kaklamani, MD, DSc, Professor of Medicine and Head of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, moderated a press conference where Milan Radovich, PhD, reported the robust ability of circulating tumor DNA (ctDNA) and circulating tumor cells to predict...
Studies Show Circulating Tumor Material May Predict Outcomes After Neoadjuvant Therapy for Breast Cancer
In early triple-negative breast cancer, the presence of circulating tumor DNA (ctDNA) and circulating tumor cells after neoadjuvant chemotherapy may enable risk stratification of patients for disease recurrence and may predict outcomes, according to a preplanned correlative analysis of the phase II ...
Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they “are...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Novel Treatment Strategies Under Study in Advanced Melanoma
Several novel strategies for the treatment of patients with stage III or IV melanoma showed promise in studies presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1,2 Vaccine for High-Risk Patients After Resection A tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was...
Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation
In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...
Mehdi Hamadani, MD: In My Experience Question 4
How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic? Recorded April 21, 2020.
Dexrazoxane, Cardiac Function, and Treatment Outcomes in Pediatric AML
In a study reported in the Journal of Clinical Oncology, Getz et al found that use of dexrazoxane was associated with preservation of cardiac function in pediatric patients receiving front-line treatment for acute myeloid leukemia (AML) and resulted in no adverse effects on treatment outcomes. As...
AACR 2020: Atezolizumab Alone or in Combination With Cobimetinib for Biliary Tract Cancer
A randomized multicenter study of a combination of immunotherapy with a targeted therapy improved cancer control for some patients with biliary tract cancer, according to research presented by Yarchoan et al at the American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract...
FDA Issues Emergency Use Authorization for Remdesivir for Treatment of Severe COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as low...
Outcomes With Autologous-Allogeneic vs Tandem Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
In a pooled analysis reported in the journal Bone Marrow Transplantation, Costa et al found that autologous followed by reduced-intensity conditioning allogeneic hematopoietic cell transplantation (auto-allo) was associated with longer overall survival compared with tandem autologous...
ASCO Survey on Early Impact of COVID-19 on the Performance of Oncology Clinical Trials
An article by Waterhouse et al in JCO Oncology Practice presented results of a recent ASCO survey of clinical programs exploring the early impact of the COVID-19 pandemic on the performance of oncology clinical trials. Results highlighted the numerous issues faced by the programs, steps that are...
FDA Pipeline: Priority Review in AML, Fast Track Designations for Pancreatic Cancer and Neuroendocrine Tumors
Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...
Managing Multiple Myeloma During the COVID-19 Pandemic
In dealing with coronavirus disease 2019 (COVID-19), some oncologists are modifying conventional treatment regimens to limit patients’ visits to infusion centers and providers’ offices. The ASCO Post asked C. Ola Landgren, MD, PhD, Chief of the Myeloma Service at Memorial Sloan Kettering Cancer...
Risk-Prediction Model for Pancreatic Cancer
A risk-prediction model that combined genetic and clinical factors with circulating biomarkers may help to identify people at a significantly higher-than-normal risk of developing pancreatic cancer, according to results of a study published by Peter Kraft, PhD, and colleagues in Cancer...
AACR 2020: Cell-Free DNA Liquid Biopsy May Provide an Early Detection Test for Patients With Suspected Cancer
The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early detection test. In this phase ...
AACR 2020: Continuous vs Intermittent Dabrafenib/Trametinib Dosing in Patients With BRAF-Mutated Melanoma
A randomized clinical trial offers evidence that a combination of two targeted melanoma drugs, when given continuously, improves progression-free survival when compared with intermittent treatment, according to study results presented by Algazi et al at the American Association for Cancer Research...
AACR 2020: ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer
The TRACERx study investigated phylogenetic tracking and minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) profiling following resection in patients with stage I to III non–small cell lung cancer (NSCLC). Investigators found that ctDNA is an adjuvant biomarker capable of...
Isatuximab-irfc for Previously Treated Multiple Myeloma
On March 2, 2020, the CD-38-directed cytolytic antibody isatuximab-irfc (Sarclisa) was approved for use in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.1,2...
FDA Accelerates Development of Novel Therapies for COVID-19
The U.S. Food and Drug Administration (FDA) has implemented a program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new...
Gut Bacterial Diversity: A Marker or Driver of Outcomes After Hematopoietic Cell Transplantation?
Previous single-center studies have linked the gut microbiota (via stool sample analysis) to outcomes after hematopoietic cell transplantation (HCT), such as overall mortality, transplant-related mortality, graft-vs-host disease, and graft-vs-host–related mortality.1-4 Although intriguing, these...
Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
Unnecessary Barrier to Blood Donation for British Nationals?
I read with great interest Jo Cavallo’s article “Maintaining Blood Donations During the COVID-19 Pandemic”. My wife and I have been British residents in the United States for over 6 years and are frustrated that we cannot donate blood, especially during this raging global COVID-19 pandemic, when...
Intermittent Dawn-to-Sunset Fasting and Anticancer Serum Proteome
In a small study published in the Journal of Proteomics, Ayse Leyla Mindikoglu, MD, MPH, and colleagues found that dawn-to-sunset fasting was associated with proteins that were protective against cancer as well as obesity, diabetes, metabolic syndrome, inflammation, and some neurologic disorders...
